P. R. Rajagopalan

REDUCTION OF THE OCCURRENCE OF ACUTE CELLULAR REJECTION AMONG RENAL ALLOGRAFT RECIPIENTS TREATED WITH BASILIXIMAB, A CHIMERIC ANTI-INTERLEUKIN-2-RECEPTOR MONOCLONAL ANTIBODY1,2

Barry D. Kahan, P. R. Rajagopalan, Michael Hall · Transplantation · 1999 · 483 citations

Life Sciences, Immunology, Pharmacology +17

Everolimus versus Mycophenolate Mofetil in the Prevention of Rejection in De Novo Renal Transplant Recipients: A 3-Year Randomized, Multicenter, Phase III Study

Marc I. Lorber, Shamkant Mulgaonkar, Khalid M.H. Butt et al. · Transplantation · 2005 · 232 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

A Phase I/II Randomized Open-Label Multicenter Trial of Efalizumab, a Humanized Anti-CD11a, Anti-LFA-1 in Renal Transplantation

Flavio Vincenti, R. Méndez, Mark D. Pescovitz et al. · American Journal of Transplantation · 2007 · 165 citations

Medicine, Immunology, Nephrology +11

Treatment of Thrombosed Dialysis Access Grafts: Randomized Trial of Surgical Thrombectomy versus Mechanical Thrombectomy with the Amplatz Device

Renan Uflacker, P. R. Rajagopalan, Ivan Vujic et al. · Journal of Vascular and Interventional Radiology · 1996 · 113 citations

Medicine, Nephrology, Surgery +14

Randomized Controlled Trial of FTY720 Versus MMF in De Novo Renal Transplantation

Hélio Tedesco‐Silva, Mark D. Pescovitz, Diane M. Cibrik et al. · Transplantation · 2006 · 108 citations

Medicine, Pharmacology, Pharmacotherapy +16